WMJ-J-09
Based on 1 Customer Validation
WMJ-J-09 is an HDAC inhibitor with IC50 values of 7.5 nM (HDAC1), 21.3 nM (HDAC2), 18.4 nM (HDAC3), 90.9 nM (HDAC8), 3.9 nM (HDAC6) and 8715.7 nM (HDAC4). WMJ-J-09 blocks the cell cycle and induces apoptosis in cancer cells. WMJ-J-09 induces cancer cell death through the LKB1-AMPK-p38MAPK-p63-survivin signaling cascade.WMJ-J-09 inhibits HDAC enzyme activity, leading to acetylation of key proteins and thereby regulating cancer cell death. WMJ-J-09 can be used in HCT116 cells and FaDu cells research[1][2].
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 98.44%
- CAS No.: 2416914-29-7
- 화학식: C22H27N3O5S
- 분자량:445.53
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
All AMPK Isoforms
More
Biological Activity
제품 설명
In Vitro
WMJ-J-09 (compound WMJ-J-09) (0-10 μM, 48 h, CRC cells) (0-20 μM, 72 h, HNSCC cells) selectively kills cancer cells in a concentration- and time-dependent manner, and exerts no significant toxicity on non-tumor FHC cells[1][2].
WMJ-J-09 (5 μM, 24 h, HCT116 cells) (10 μM, 48 h, FaDu cells) arrests the cell cycle of cancer cells at the G2/M phase and induces apoptosis[1][2].
WMJ-J-09 (5 μM, 24 h, HCT116 cells) (10 μM, 24 h, FaDu cells) disrupts microtubule assembly[1][2].
WMJ-J-09 (5 μM, 6-24 h, HCT116 cells) (10 μM, 24 h, FaDu cells) inhibits survivin at the transcriptional level[1][2].
WMJ-J-09 (0-10 μM, 24 h, HCT116 cells) (0-20 μM, 48 h, FaDu cells) regulates signaling pathways in cancer cells, inhibits HDACs to modulate key proteins, and promotes cancer cell apoptosis[1][2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HCT116 cells, FHC cells; FaDu cells, SCC9 cells, SCC25 cells
-
Concentration:0.1 μM, 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM (HCT116 cells, FHC cells); 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 20 μM (FaDu cells, SCC9 cells, SCC25 cells)
-
Incubation Time:48 h (HCT116 cells, FHC cells); 72 h (FaDu cells, SCC9 cells, SCC25 cells)
-
Result:Reduced the viability of CRC cells (with significant inhibition at 10 μM and an IC50 of approximately 5 μM).
Had the strongest inhibitory effect on cell viability at 10 μM, and the survival rate of FaDu cells dropped to about 30 % after treatment with 20 μM for 72 h.
-
Cell Line:HCT116 cells; FaDu cells
-
Concentration:5 μM (HCT116 cells); 10 μM (FaDu cells)
-
Incubation Time:24 h (HCT116 cells); 48 h (FaDu cells)
-
Result:Increased the proportion of early apoptotic (LR quadrant) and late apoptotic (UR quadrant) cells.
Increased cleaved caspase-3 and PARP cleavage fragments.
Significantly increased the proportion of sub-G1 phase (apoptotic cells), with approximately 40 % at 20 μM.
-
Cell Line:HCT116 cells; FaDu cells
-
Concentration:5 μM (HCT116 cells); 0.1 μM, 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 20 μM (FaDu cells)
-
Incubation Time:24 h
-
Result:Reduced the proportion of cells in the S phase and increased the proportion of cells in the G2/M phase and sub-G1 phase (apoptosis peak).
Increased the proportion of cells in the G2/M phase (from 12 % to 28 % at 10 μM) and decreased the number of cells in the S phase.
-
Cell Line:HCT116 cells; FaDu cells
-
Concentration:5 μM (HCT116 cells); 10 μM (FaDu cells)
-
Incubation Time:24 h
-
Result:Disrupted the cytoskeleton through α-tubulin acetylation.
-
Cell Line:HCT116 cells; FaDu cells
-
Concentration:5 μM (HCT116 cells); 10 μM (FaDu cells)
-
Incubation Time:6-24 h (HCT116 cells); 6 h (FaDu cells)
-
Result:Inhibited survivin expression at the transcriptional level.
-
Cell Line:HCT116 cells, HCT116 p53-/- cells, HCT116-p53 wildtype cells; FaDu cells
-
Concentration:0.1 μM, 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM (HCT116 cells, HCT116 p53-/- cells, HCT116-p53 wildtype cells); 2.5 μM, 5 μM, 10 μM, 20 μM (FaDu cells)
-
Incubation Time:24 h (HCT116 cells, HCT116 p53-/- cells, HCT116-p53 wildtype cells); 48 h (FaDu cells)
-
Result:Increased p21 protein, acetylated and phosphorylated p53, decreased survivin protein, and increased α-tubulin acetylation.
Activated phosphorylation of the LKB1/p38MAPK pathway.
Acetylated survivin and degraded it in the proteasome.
Increased p21 protein significantly, while cyclin D1 and survivin proteins decreased.
Increased the phosphorylation levels of LKB1 (Ser 428), AMPK (Thr 172), p38MAPK (Thr 180/Tyr 182), and p63 (Ser 160/162) over time, and increased cleaved caspase-3 and PARP (apoptosis markers).
In Vivo
WMJ-J-09 (compound WMJ-J-09) (20 mg/kg, i.p, daily for 19 days) inhibits CRC tumor growth by inhibiting cancer cell proliferation and is well tolerated in the HCT116 xenograft mice model[1].
WMJ-J-09 (20 mg/kg, i.p, daily for 23 days) inhibits the growth of HNSCC transplanted tumors and has good safety[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:HCT116 xenograft model established in nude male mice(4 weeks)[1]
-
Dosage:20 mg/kg
-
Administration:Daily intraperitoneal injection (i.p.), at the corresponding doses for 19 days
-
Result:Inhibited tumor growth, with tumor volume and weight significantly lower than those in the control group.
Inhibited tumor proliferation, as indicated by reduced Ki67 immunohistochemical staining within the tumor.
Exhibited low toxicity, with no significant change in mouse body weight.
-
Animal Model:DaFu xenograft model established in nude male mice(4 weeks, 25g)[2]
-
Dosage:20 mg/kg
-
Administration:Daily intraperitoneal injection (i.p.), at the corresponding doses for 23 days.
-
Result:Significantly inhibited tumor growth, with the average tumor weight in the treatment group lower than that in the control group.
Exhibited low toxicity, with no significant change in mouse body weight.
Chemical Information
-
CAS No. 2416914-29-7
-
Appearance Solid
-
분자량 445.53
-
화학식 C22H27N3O5S
-
Color White to off-white
-
SMILES
O=C(NO)CCCCCCC(NC1=CC(N(S(C2=CC=CC=C2)(=O)=O)CC3)=C3C=C1)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
용액&용해도
In Vitro:
DMSO : 250 mg/mL (561.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocol
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
순도&문서
-
Data Sheet (281 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Hanhuang Yu, et al. The hydroxamate based HDAC inhibitor WMJ-J-09 induces [Content Brief]
[2]. Chia-Sheng Yen, et al. A Novel Hydroxamate-Based Compound WMJ-J-09 Causes Head and Neck Squamous Cell Carcinoma Cell Death via LKB1-AMPK-p38MAPK-p63-Survivin Cascade. Front Pharmacol. 2018 Mar 1. 9:167. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2445 mL | 11.2226 mL | 22.4452 mL | 56.1129 mL |
| 5 mM | 0.4489 mL | 2.2445 mL | 4.4890 mL | 11.2226 mL | |
| 10 mM | 0.2245 mL | 1.1223 mL | 2.2445 mL | 5.6113 mL | |
| 15 mM | 0.1496 mL | 0.7482 mL | 1.4963 mL | 3.7409 mL | |
| 20 mM | 0.1122 mL | 0.5611 mL | 1.1223 mL | 2.8056 mL | |
| 25 mM | 0.0898 mL | 0.4489 mL | 0.8978 mL | 2.2445 mL | |
| 30 mM | 0.0748 mL | 0.3741 mL | 0.7482 mL | 1.8704 mL | |
| 40 mM | 0.0561 mL | 0.2806 mL | 0.5611 mL | 1.4028 mL | |
| 50 mM | 0.0449 mL | 0.2245 mL | 0.4489 mL | 1.1223 mL | |
| 60 mM | 0.0374 mL | 0.1870 mL | 0.3741 mL | 0.9352 mL | |
| 80 mM | 0.0281 mL | 0.1403 mL | 0.2806 mL | 0.7014 mL | |
| 100 mM | 0.0224 mL | 0.1122 mL | 0.2245 mL | 0.5611 mL |